- Home
- FCO vs CTMX Comparison
FCO vs CTMX Comparison
Compare FCO & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCO
- CTMX
- Stock Information
- Founded
- FCO 1991
- CTMX 2008
- Country
- FCO United Kingdom
- CTMX United States
- Employees
- FCO N/A
- CTMX N/A
- Industry
- FCO Investment Managers
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- FCO Finance
- CTMX Health Care
- Exchange
- FCO Nasdaq
- CTMX Nasdaq
- Market Cap
- FCO 81.4M
- CTMX 89.1M
- IPO Year
- FCO N/A
- CTMX 2015
- Fundamental
- Price
- FCO $5.97
- CTMX $0.91
- Analyst Decision
- FCO
- CTMX Buy
- Analyst Count
- FCO 0
- CTMX 6
- Target Price
- FCO N/A
- CTMX $5.77
- AVG Volume (30 Days)
- FCO 100.1K
- CTMX 1.1M
- Earning Date
- FCO 01-01-0001
- CTMX 11-07-2024
- Dividend Yield
- FCO 14.96%
- CTMX N/A
- EPS Growth
- FCO N/A
- CTMX N/A
- EPS
- FCO 0.43
- CTMX 0.16
- Revenue
- FCO N/A
- CTMX $126,617,000.00
- Revenue This Year
- FCO N/A
- CTMX $11.79
- Revenue Next Year
- FCO N/A
- CTMX N/A
- P/E Ratio
- FCO $12.30
- CTMX $5.63
- Revenue Growth
- FCO N/A
- CTMX 33.66
- 52 Week Low
- FCO $4.73
- CTMX $0.91
- 52 Week High
- FCO $6.63
- CTMX $5.85
- Technical
- Relative Strength Index (RSI)
- FCO 48.57
- CTMX 32.42
- Support Level
- FCO $5.96
- CTMX $0.98
- Resistance Level
- FCO $6.16
- CTMX $1.08
- Average True Range (ATR)
- FCO 0.10
- CTMX 0.06
- MACD
- FCO -0.00
- CTMX -0.00
- Stochastic Oscillator
- FCO 43.18
- CTMX 0.00
About FCO abrdn Global Income Fund Inc.
abrdn Global Income Fund Inc is a closed-end, non-diversified management investment company. The Fund's principal investment objective is to provide high current income by investing predominantly in fixed-income securities. As a secondary investment objective, the Fund seeks capital appreciation, but only when consistent with its principal investment objective. It invests in Government Bonds & Corporate Bonds, and its investments are divided into three categories, Developed Markets, Investment Grade Developing Markets, and Sub-Investment Grade Developing Markets.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.